Amphastar Pharmaceuticals' (NASDAQ:AMPH) Three-year Earnings Growth Trails the Stellar Shareholder Returns
Amphastar Pharmaceuticals' (NASDAQ:AMPH) Three-year Earnings Growth Trails the Stellar Shareholder Returns
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money. For example, the Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) share price has soared 162% in the last three years. How nice for those who held the stock! On top of that, the share price is up 19% in about a quarter.
任何股票的最大亏损(假设您不使用杠杆)就是您的全部资金100%。但是如果您购买了一家很棒的公司的股票,您的收益可能超过您的投入。例如,Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)的股票价格在过去三年里飙升了162%。持有该股票的人真是太幸运了!此外,股票价格在一个季度时间里上涨了19%。
After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.
在过去的一周之内,获得的强劲收益是否表明了长期回报受到基本面的推动值得关注。
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
用本杰明·格雷厄姆的话来说:“短期市场是一台投票机,但长期市场是一台称重机”。检查市场情绪如何随时间推移变化的一种方式是查看公司股价和每股收益(EPS)之间的相互作用。
During three years of share price growth, Amphastar Pharmaceuticals achieved compound earnings per share growth of 150% per year. The average annual share price increase of 38% is actually lower than the EPS growth. So it seems investors have become more cautious about the company, over time.
在三年的股价上涨中,Amphastar Pharmaceuticals每股收益复合增长率达到了150%每年。年均股价增长率为38%,实际上低于每股收益的增长率。所以看起来投资者对该公司逐渐变得更加谨慎了。
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下图显示了EPS随时间的变化情况(如果您单击该图像,则可以查看更多详细信息)。
It is of course excellent to see how Amphastar Pharmaceuticals has grown profits over the years, but the future is more important for shareholders. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.
当然,看到Amphastar Pharmaceuticals多年来利润增长是非常好的,但对股东来说,未来更重要。建议您查看我们关于其财务状况如何随时间变化的免费报告。
A Different Perspective
不同的观点
Amphastar Pharmaceuticals shareholders are up 5.1% for the year. Unfortunately this falls short of the market return. If we look back over five years, the returns are even better, coming in at 18% per year for five years. Maybe the share price is just taking a breather while the business executes on its growth strategy. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Amphastar Pharmaceuticals has 1 warning sign we think you should be aware of.
Amphastar Pharmaceuticals股东今年的收益率为5.1%,不幸的是这低于市场回报。如果我们回顾过去五年,回报率更好,达到每年18%。也许股价只是在实施增长策略时稍作休整。虽然考虑市场状况对股价的不同影响是值得的,但还有其他更重要的因素。例如,要承担风险——Amphastar Pharmaceuticals有1个警示标志,我们认为您应该知道。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
当然,您可能在其他地方找到一家出色的企业进行投资。因此,请查看我们预计将实现盈利增长的公司的免费列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。